Breaking News
Novartis
About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125 000 people of more than 140 nationalities work at Novartis around the world.
Novartis Trial Shows Benefit in Patients with Breast Cancer
March 27 2023
Novartis today announced positive topline results from an interim analysis of NATALEE, a Phase III […]
Dawn Health partners with leading Pharmaceutical Company, Novartis, to Transform Chronic Care
February 23 2023
Dawn Health, a global leader in digital health, has announced a strategic partnership with Novartis, […]
Novartis Appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.d., Steps Down From the Executive Committee of Novartis
September 2 2022
Novartis today announced that James (Jay) E. Bradner, M.D., will step down from the Executive […]
Marie- Andrée Gamache Appointed Country President, Novartis Innovative Medicines, UK & Ireland
August 25 2022
Novartis UK is announcing that Marie-Andrée Gamache has been appointed to the role of Country […]
MHRA Grants Marketing Authorisation for Novartis’ Radioligand Therapy Pluvicto®▼ (Lutetium (¹⁷⁷lu) Vipivotide Tetraxetan) in Advanced Prostate Cancer in Great Britain
August 15 2022
Advanced Accelerator Applications (AAA), a Novartis company, today announced that the Medicines & Healthcare products […]
NICE Recommends Novartis’ Piqray ® (Alpelisib) as a Targeted Treatment for Thousands of Advanced Breast Cancer Patients
July 18 2022
Today Novartis Pharmaceuticals UK announces that the National Institute for Health and Care Excellence (NICE) […]
Thousands Of Patients To Benefit As NHS Marks 100th Fast-Tracked Cancer Drug
July 15 2022
Thousands of people a year with advanced breast cancer will benefit from a life-extending drug […]
Novartis Pharmaceuticals UK Launches World-first Health-tech Investor Partnership to Reimagine Cardiovascular Care
July 6 2022
Novartis Pharmaceuticals UK announces the launch of the Novartis Biome UK Heart Health Catalyst 2022, […]
New Phase III Data Show Novartis Tislelizumab Significantly Extended Median Overall Survival by More Than 6 Months in First-line Advanced Esophageal Cancer in Combination With Chemotherapy
July 4 2022
Today Novartis announced results from the Phase III RATIONALE 306 trial showing tislelizumab plus chemotherapy […]
Novartis Receives GB Licence for Scemblix®▼ (Asciminib), the First STAMP Inhibitor for Patients With Chronic Myeloid Leukaemia
June 17 2022
Novartis UK has announced that Scemblix® (asciminib) has been granted Marketing Authorisation in Great Britain by […]
New Novartis Data Show Piqray® Effectiveness Across Key Biomarkers in Patients With HR+/HER2- Metastatic Breast Cancer
June 6 2022
Novartis today announced results of an exploratory retrospective biomarker analysis finding that different genetic mutation […]
Novartis UK Launches New Heart Failure Insights Tool to Address Health Inequalities in England
May 30 2022
Novartis UK has today announced the launch of a new heart failure Health Inequalities Insights […]
New Novartis Data Demonstrate Only Kisqali® Offers More Life in the First-line Setting for Postmenopausal HR+/HER2- Advanced Breast Cancer Patients
May 4 2022
Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant […]
Novartis Tislelizumab plus Chemotherapy Significantly Improved Overall Survival as First-line Treatment for Advanced Esophageal Cancer in Phase III Study
April 29 2022
Novartis today announced positive topline results from an interim analysis of the Phase III RATIONALE […]
Novartis Pluvicto™ Approved by FDA as First Targeted Radioligand Therapy for Treatment of Progressive, PSMA-positive Metastatic Castration-resistant Prostate Cancer
March 24 2022
Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu […]
Novartis to Acquire Gyroscope Therapeutics, Adding a One-time Gene Therapy That Could Transform Care for Geographic Atrophy, a Leading Cause of Blindness
December 22 2021
Novartis announced today that it entered into a definitive agreement to acquire all of the […]
Novartis Launches Virtual Innovation Hub to Accelerate Digital Health Solutions in Sub-Saharan Africa
November 25 2021
Novartis has announced the launch of its new innovation hub, Novartis Biome sub-Saharan Africa (SSA), […]
Dunad Therapeutics Enters Strategic Collaboration with Novartis to Develop Next-generation Oral Targeted Protein Degrader Therapies
November 2 2021
Dunad Therapeutics (“Dunad”), a biopharmaceutical company focusing on the development of next-generation targeted protein degradation […]
Novartis Awarded Promising Innovative Medicine Designation for Targeted Radioligand Theragnostics in Prostate Cancer
October 20 2021
Novartis today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Promising […]
NHS Announces Deal for Life Changing Sickle Cell Treatment
October 5 2021
The first treatment for sickle cell disease in over 20 years will be rolled out […]
Novartis Acquires Arctos Medical, Expanding Optogenetics Portfolio to Bring Gene Therapies to Patients with Severe Vision Loss
September 21 2021
Novartis today announced that it has acquired Arctos Medical, adding a pre-clinical optogenetics-based AAV gene […]
World-first Agreement Between Novartis and the NHS Enables Broad and Rapid Access to First-in-class Cholesterol-lowering Medicine Leqvio® ▼(inclisiran)
September 1 2021
Novartis has reached a commercial agreement with the NHS in England as part of a […]
Kesimpta® (Ofatumumab) Data Show Long-term Preservation of IgG/IgM Levels and no Increased Risk of Serious Infections in People Living with Multiple Sclerosis
June 22 2021
Today, Novartis disclosed new data showing mean IgG and IgM levels remain unchanged in adults […]
Novartis Announces Iptacopan Met Phase II Study Primary Endpoint in Rare Kidney Disease IgA Nephropathy (IgAN)
June 7 2021
Novartis today announced Phase II primary endpoint data showing investigational iptacopan (LNP023) – a first-in-class, […]
Novartis Presents Positive Phase III Results From JUNIPERA Study Supporting Cosentyx® as a Potential Treatment in a JIA Population at EULAR 2021
June 2 2021
Novartis, a leader in rheumatology and immuno-dermatology, today announced 2-year positive results from the Phase […]
NHS Treats First Patient with the ‘World’s Most Expensive Drug’
June 1 2021
A five-month old baby has become the first patient to receive a potentially life-saving drug […]